Overview

This trial is active, not recruiting.

Conditions hematological diseases, invasive aspergillosis
Sponsor Ospedale Santa Croce-Carle Cuneo
Start date May 2002
End date June 2007
Trial size 220 participants
Trial identifier NCT00838643, Gal-01

Summary

Evaluation of incidence of invasive aspergillosis in patients who have undergone an allogeneic stem cell transplantation, with particular regard to the role of galactomannan assay and of early TC scan in asymptomatic patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Adult allogeneic HSCT recipients

Primary Outcomes

Measure
Incidence of invasive aspergillosis
time frame: 1 year

Secondary Outcomes

Measure
Clinical applicability of the EORTC/MSG criteria in a prospective multicenter trial
time frame: 1 year

Eligibility Criteria

Male or female participants at least 16 years old.

Inclusion Criteria: - Age > 16 years - Allogeneic HSCT for a haematological disease - Written informed consent to the study Exclusion Criteria: - Pediatric patients

Additional Information

Official title Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: an Italian Prospective Multicentre Study
Trial information was received from ClinicalTrials.gov and was last updated in February 2009.
Information provided to ClinicalTrials.gov by Ospedale Santa Croce-Carle Cuneo.